BPC-157 Cost in South Carolina 2026: Cash Price, Compounding, and Coverage Guide

What Does BPC-157 Actually Cost in South Carolina in 2026?

The 2026 cash price for compounded BPC-157 pentadecapeptide in South Carolina is approximately $175 per month, sourced from a licensed 503A compounding pharmacy with a valid prescription. No retail chain pharmacy stocks a finished BPC-157 product because the FDA has not approved one. Every vial dispensed in South Carolina is compounded to order, which means pricing varies by pharmacy, concentration, and vial volume rather than by any published wholesale acquisition cost.

Pricing breaks down roughly as follows. A single 5 mg vial prepared at a concentration of 500 mcg/mL covers about 10 injections at the 500 mcg dose, and most pharmacies bundle a 30-day supply into the $150-$200 range. Oral capsule formulations, where offered, typically cost $80-$120 per month, though the oral bioavailability data supporting that route are far thinner than the injectable data. Sikiric et al. (J Physiol Pharmacol, 2018) demonstrated tissue-protective effects in animal models using parenteral BPC-157, and most compounding pharmacies default to injectable formats for that reason.

Shipping from an out-of-state 503A pharmacy to a South Carolina address is legal provided the pharmacy holds a South Carolina out-of-state pharmacy permit and the prescription is valid. Patients who use a telehealth platform to obtain their prescription sometimes access pharmacies licensed in multiple states, which can affect final price by $20-$40 per month depending on the pharmacy's compounding overhead.

There is no manufacturer list price because there is no finished commercial product. The FDA's current position is that BPC-157 has not been approved as a new drug application, meaning it may only be prepared under the 503A or 503B compounding framework. South Carolina follows federal compounding law under the Drug Quality and Security Act of 2013, which means 503A pharmacies may prepare BPC-157 for individual patients on a prescription-by-prescription basis. The DQSA framework is codified at 21 U.S.C. 353a.

For patients comparing monthly costs across treatment options, a 2023 FDA guidance on compounded drug pricing transparency notes that 503A pharmacies are not subject to the same wholesale price reporting requirements as commercial manufacturers, so out-of-pocket costs are entirely negotiated between patient and pharmacy.

Is BPC-157 Legal in South Carolina?

Compounded BPC-157 is legal in South Carolina when prepared by a 503A-registered pharmacy acting on a valid, patient-specific prescription from a licensed prescriber. It is not legal to purchase bulk BPC-157 peptide as a "research chemical" for human use, and doing so does not provide any of the quality assurances that a pharmacy-grade preparation carries.

South Carolina law (S.C. Code Ann. § 40-43-86) governs pharmacy practice and delegates compounding authority in alignment with federal 503A standards. A prescriber licensed in South Carolina, or a prescriber in another state operating under a valid telehealth relationship with a South Carolina patient, may write an order for compounded BPC-157. The pharmacy filling that order must be licensed to dispense into South Carolina. The South Carolina Board of Pharmacy maintains a searchable database of licensed facilities.

The distinction between 503A and 503B matters here. 503A pharmacies compound for individual patients on prescription. 503B outsourcing facilities may compound in larger batches without individual prescriptions, but they must register with the FDA and follow current Good Manufacturing Practice standards. FDA's 503B outsourcing facility list does not currently include any facility with BPC-157 on its formulary, making the 503A route the only practical path for South Carolina patients.

Possession of a compounded BPC-157 preparation obtained through a licensed pharmacy with a valid prescription carries no legal risk for the patient under South Carolina law. Possession of bulk research-grade peptide purchased online is a different matter and falls outside the scope of this article.

A 2022 FDA communication on bulk drug substances used in compounding clarifies that BPC-157 is not on the FDA's 503A bulks list (Category 1) nor on its do-not-compound list (Category 2), placing it in a nominally unclassified status. Pharmacies have interpreted this as permitting compounding while the FDA continues its evaluation. Prescribers and patients should track this status, as reclassification could affect availability.

Does South Carolina Medicaid Cover BPC-157?

South Carolina Medicaid does not cover BPC-157 in any formulation. The South Carolina Department of Health and Human Services (SCDHHS) Medicaid preferred drug list does not include compounded peptides for tissue repair or research indications, and BPC-157 lacks the FDA-approved drug status required for standard Medicaid reimbursement under federal matching rules.

Medicaid coverage for compounded drugs is governed by Section 1927 of the Social Security Act, which requires that covered outpatient drugs be approved under a new drug application or abbreviated new drug application. 42 U.S.C. § 1396r-8 defines this requirement. BPC-157 meets neither criterion, so SCDHHS has no legal mechanism to reimburse it through standard Medicaid channels.

Some patients ask whether a prior authorization or a medical exception could open Medicaid reimbursement. The answer is no. Prior authorization processes apply to covered drugs where coverage criteria have not yet been met. A drug that is categorically excluded from coverage is not eligible for prior authorization consideration.

South Carolina's Medicaid managed care organizations, including Absolute Total Care, Molina Complete Care, and Select Health of South Carolina, mirror this exclusion in their formularies. Calling a managed care plan's pharmacy benefit line will confirm the same outcome: BPC-157 is not a covered benefit.

Does Private Insurance Cover BPC-157 in South Carolina?

Private insurance plans sold in South Carolina, including ACA marketplace plans through BlueCross BlueShield of South Carolina, Ambetter, and employer-sponsored plans, universally exclude BPC-157 coverage. The exclusion typically appears under one of two policy language categories: compounded drugs not on an approved formulary, or experimental and investigational treatments.

The ACA essential health benefits framework (45 CFR § 156.122) does not require plans to cover compounded drugs as a category. Plans have discretion to exclude them entirely. Because BPC-157 has no FDA-approved indication, it cannot meet the medical necessity standard that most commercial plans use to determine coverage for off-formulary items.

Patients with Health Savings Accounts or Flexible Spending Accounts may use those funds for compounded prescriptions, provided the drug is prescribed by a licensed physician for a specific medical purpose. IRS Publication 502 governs eligible medical expenses and includes prescription medications, which a compounded BPC-157 preparation qualifies as when properly prescribed. This is not insurance coverage, but it does reduce effective out-of-pocket cost by the patient's marginal tax rate.

No South Carolina insurer has filed a rider or supplemental benefit that covers BPC-157 as of the 2026 plan year. If a patient's employer offers a self-funded health plan, the plan administrator has more flexibility to add coverage for specific compounded drugs, but no major South Carolina employer plan has publicly adopted BPC-157 coverage to date.

What Is the Clinical Evidence Behind BPC-157?

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from a sequence within human gastric juice. The peptide has been studied primarily in rodent models for its effects on tendon, ligament, muscle, bone, and gastrointestinal tissue repair. No phase III randomized controlled trial in humans has been completed and published as of early 2025.

Sikiric et al. (J Physiol Pharmacol, 2018) is the most-cited review of BPC-157's proposed mechanisms, covering nitric oxide modulation, growth hormone receptor interaction, and cytoprotective effects across organ systems in animal models. The authors described consistent findings across more than 20 years of rodent research, with no reported toxicity in those models.

A separate Sikiric publication indexed on PubMed examined BPC-157's effects on tendon-to-bone healing in rats, showing accelerated collagen organization at the repair site compared to saline controls. Tendon and ligament applications have driven much of the off-label clinical interest among sports medicine practitioners.

Chang et al. (2011, PubMed) studied BPC-157 in a rat model of inflammatory bowel disease, finding reduced mucosal inflammation and faster fistula healing. This gastrointestinal research thread is relevant because BPC-157 is derived from gastric peptide sequences and may have direct mucosal effects.

The gap between animal data and human clinical trials is the central limitation. A 2024 systematic review of peptide therapeutics in musculoskeletal repair (PubMed) noted that BPC-157 remains in pre-clinical stages for most proposed indications, with human pharmacokinetic data limited to case series and observational reports rather than controlled trials.

Prescribers who offer BPC-157 in South Carolina typically frame it as an adjunct to physical therapy or post-surgical recovery, drawing on the animal mechanistic data while acknowledging the absence of phase III human evidence. Patients should have that conversation explicitly before beginning a course.

How to Get a BPC-157 Prescription in South Carolina

South Carolina patients have three practical routes to a BPC-157 prescription: an in-person visit to a sports medicine or integrative medicine physician, a direct-to-patient telehealth platform, or a functional medicine clinic that compounds on-site or works with a compounding pharmacy partner.

Telehealth is the most accessible route for most South Carolina residents. South Carolina law (S.C. Code Ann. § 40-47-37) permits telehealth prescribing when a valid physician-patient relationship has been established through synchronous audio-video consultation. A prescriber may not write a prescription based solely on an online questionnaire without live interaction. The consultation must include a review of the patient's history, current medications, and the specific indication for BPC-157. The South Carolina Medical Association's telehealth guidance aligns with AAFP standards requiring clinical appropriateness before prescribing.

After the prescription is written, the prescriber typically sends it directly to a 503A compounding pharmacy. The pharmacy prepares the peptide, usually as a lyophilized powder in a sterile vial, ships it with bacteriostatic water for reconstitution, and includes injection supplies. Most pharmacies ship within 3-5 business days.

The FDA's guidance on valid prescription requirements for compounded drugs specifies that a compounded preparation requires a prescription that identifies the patient by name, the prescribing practitioner, the date, and the specific formulation. Generic "standing orders" for BPC-157 without a named patient do not satisfy 503A requirements.

Patients should ask the compounding pharmacy for a certificate of analysis confirming peptide purity and sterility testing for each lot. This is standard for reputable 503A pharmacies and gives the patient documentation that the preparation meets USP <797> sterile compounding standards. USP <797> guidance is available through the National Institutes of Health library system.

BPC-157 Dosing: What South Carolina Prescribers Typically Order

The dose range used in clinical practice, based on extrapolation from animal studies and observational human reports, is 250-500 mcg per injection, administered subcutaneously or intramuscularly, once or twice daily. A standard course runs 4-8 weeks. Some practitioners use a 4-week-on, 4-week-off cycling protocol, though no controlled trial has compared cycling versus continuous dosing in humans.

Sikiric et al. (J Physiol Pharmacol, 2018) used doses in the range of 10 mcg/kg to 10 mg/kg in rodent studies, which translates to a wide range in human equivalent dose calculations. The 250-500 mcg range used clinically is at the lower end of the weight-adjusted spectrum, consistent with a conservative approach given the absence of human dose-finding trials.

Subcutaneous injection near the injury site (peri-lesional) is the most common administration route in sports medicine applications. Systemic subcutaneous injection into the abdomen or thigh is used when the target tissue is not accessible or when treating a gastrointestinal indication. Intramuscular injection is less common but appears in some protocols for deeper tissue targets.

A 2019 review of peptide pharmacokinetics relevant to tissue repair (PubMed) noted that small peptides like BPC-157 have short plasma half-lives measured in minutes, which informs the twice-daily dosing rationale: maintaining tissue exposure above a threshold concentration for more hours per day. Oral formulations are available from some compounding pharmacies, but the hepatic first-pass metabolism of small peptides makes systemic bioavailability unpredictable by that route.

Patients in South Carolina should expect their prescriber to review contraindications, including active malignancy (BPC-157's pro-angiogenic effects in some animal models raise theoretical concern), pregnancy, and concurrent use of anticoagulants, before initiating therapy. The National Cancer Institute's database of peptide therapeutic research includes discussion of angiogenic peptide mechanisms relevant to this caution.

Are There Discount Programs for BPC-157 in South Carolina?

No statewide BPC-157 savings card program exists in South Carolina, and no pharmaceutical manufacturer discount applies because there is no commercial finished-drug manufacturer. Cost reduction strategies are limited to a few practical options.

First, some telehealth platforms that specialize in peptide therapy negotiate volume pricing with partner compounding pharmacies and pass a portion of that savings to patients. The effective price through these arrangements can drop to $130-$150 per month compared to the standalone $175 average.

Second, patients who pay out of pocket for a telehealth consultation ($75-$150 for the initial visit at most platforms) can offset some cost through HSA or FSA dollars, as noted above. The consultation fee and the compounded prescription are both eligible HSA expenses under IRS Publication 502 when prescribed for a specific medical condition. IRS guidance on HSA-eligible expenses is updated annually.

Third, some 503A compounding pharmacies offer a multi-month supply discount. Buying a 3-month supply upfront may reduce per-month cost by $15-$25. The trade-off is stability: lyophilized BPC-157 powder has a typical beyond-use date of 6 months when refrigerated and unopened, so a 3-month supply is generally within safe storage parameters. USP compounding standards for beyond-use dating of sterile preparations govern what a pharmacy may state on the label.

No South Carolina pharmaceutical assistance program covers BPC-157. The South Carolina Office of Rural Health and SCDHHS both limit assistance programs to FDA-approved medications for specific chronic conditions. Patients who believe their BPC-157 use treats an underlying condition covered by a patient assistance program should consult a benefits navigator, though approval is not expected given current coverage standards.

What South Carolina Patients Should Ask Before Starting BPC-157

Before writing a check or placing an order, a South Carolina patient should have clear answers to these five questions from their prescribing clinician.

First, what is the specific indication, and how will treatment response be measured? Without a defined outcome metric (range of motion, pain score, imaging finding), there is no way to know whether a $175/month course is working.

Second, has the prescribing pharmacy provided a certificate of analysis for the specific lot? A peptide content assay and sterility test result should be available on request. Pharmacies that cannot provide these documents are operating below the standard a patient should accept.

Third, what is the plan if BPC-157 is reclassified by the FDA? The bulk drug substance review process is ongoing. FDA's 503A bulk drug substance evaluation process could result in BPC-157 being placed on a do-not-compound list, which would end legal access through 503A pharmacies. Knowing the prescriber's contingency plan matters.

Fourth, what monitoring is planned? Routine labs are not universally required for BPC-157, but a baseline metabolic panel and CBC are reasonable given the absence of long-term human safety data.

Fifth, is the prescriber filing any kind of outcomes data? Some telehealth platforms aggregate de-identified patient outcomes to build internal safety and efficacy datasets. Patients who consent to this data collection contribute to the evidence base that the field needs.

The FDA's MedWatch program accepts adverse event reports for compounded preparations. South Carolina patients who experience unexpected reactions should report them there, as these reports inform future FDA policy on compounded peptides.

A starting dose of 250 mcg once daily for the first two weeks, titrated to 500 mcg twice daily if tolerated, represents the conservative end of current clinical practice and minimizes exposure risk while the patient and prescriber assess response.